CARsgen Announced 2024 Annual Results

CARsgen Announced 2024 Annual Results

SHANGHAI, March 19, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results. Business Highlights Zevor-cel was approved by...

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib...

menu
menu